Wells Fargo’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wells Fargo’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$111M	Hold	370,000	–	–	0.02%	636
2026 Q1	$122M	Hold	370,000	–	–	0.02%	556
2025 Q4	$147M	Buy	370,000 +350,000	+1,750%	+$155M	0.03%	479
2025 Q3	$9.12M	Hold	20,000	–	–	﹤0.01%	2086
2025 Q2	$6.52M	Hold	20,000	–	–	﹤0.01%	2265
2025 Q1	$5.4M	Hold	20,000	–	–	﹤0.01%	2351
2024 Q4	$4.71M	Buy	+20,000	New	+$5.26M	﹤0.01%	2490
2017 Q2	–	Sell	-126,600	Closed	-$332K	–	6196
2017 Q1	$332K	Buy	126,600 +95,100	+302%	+$4.4M	﹤0.01%	4516
2016 Q4	$31K	Buy	+31,500	New	+$1.32M	﹤0.01%	5511
2015 Q2	–	Sell	-56,100	Closed	-$524K	–	6319
2015 Q1	$524K	Sell	56,100 -1,900	-3%	-$193K	﹤0.01%	3912
2014 Q4	$469K	Buy	+58,000	New	+$5.37M	﹤0.01%	3983
2014 Q3	–	Sell	-20,000	Closed	-$61K	–	6158
2014 Q2	$61K	Sell	20,000 -80,000	-80%	-$4.75M	﹤0.01%	4888
2014 Q1	$67K	Sell	100,000 -5,000	-5%	-$387K	﹤0.01%	4827
2013 Q4	$562K	Buy	+105,000	New	+$6.26M	﹤0.01%	3746

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo's ALNY Position: Q2 2026 in Review

Wells Fargo reduced its Alnylam Pharmaceuticals (ALNY) stake by 9.5% in Q2 2026, selling an estimated $9.87M and leaving 310,047 shares worth $93.3M. The position accounts for 0.02% of the portfolio, ranked #713.

Wells Fargo first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $128M in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Wells Fargo held 310,047 shares of Alnylam Pharmaceuticals worth $93.3M as of Q2 2026.
Wells Fargo sold 32,716 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $9.87M.
Alnylam Pharmaceuticals made up 0.02% of Wells Fargo's portfolio in Q2 2026, its #713 holding.
Wells Fargo first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Wells Fargo's Alnylam Pharmaceuticals position peaked at $128M in Q3 2025.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.